期刊文献+

英夫利西单抗联合小剂量甲氨蝶呤治疗10例重度银屑病临床观察

原文传递
导出
摘要 生物制剂能靶向性阻断T淋巴细胞活化,阻断特异的细胞因子参与免疫反应,在欧美国家已广泛应用于银屑病等免疫介导的炎症性疾病,显示出显著的疗效及良好的安全性。我们采用英夫利西单抗(infliximab)联合甲氨蝶呤(MTX)治疗10例重度银屑病,取得良好效果,报道如下。
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2015年第11期815-816,共2页 Chinese Journal of Dermatology
  • 相关文献

参考文献10

  • 1Sfikakis PP. The first decade of biologic TNF antagonists in clinicalpractice: lessons learned, unresolved issues and future directions[J]. Curr Dir Autoimmun, 2010,11: 180- 210.
  • 2Moll JM, Wright V. Psoriatic arthritis[j]. Semin Arthritis Rheum,1973,3( 1):55-78.
  • 3Reich K, Nestle FO, Papp K, et al. Infliximab induction andmaintenance therapy for moderate-to-severe psoriasis: a phase III,multicentre, double-blind trial [J]. Lancet, 2005, 366 (9494):1367-1374.
  • 4Antoniou C,Stefanaki I,Stratigos A, et al. Infliximab for thetreatment of psoriasis in Greece: 4 years of clinical experience at asingle centre[j]. Br J Dermatol, 2010,162(5): 1117-1123.
  • 5Mease P. Infliximab ( Remicade ) in the treatment of psoriaticarthritis[j]. Ther Clin Risk Manag, 2006: 2(4): 389-400.
  • 6Arends S, Lebbink HR, Spoorenberg A, et al. The formation ofautoantibodies and antibodies to TNF-a blocking agents in relationto clinical response in patients with ankylosing spondylitis[j]. ClinExp Rheumatol, 2010, 28 ?5): 661-668.
  • 7Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signsand symptoms of psoriatic arthritis: results of the IMPACT 2 trial[J]. Ann Rheum Dis, 2005,64(8): 1150-1157.
  • 8Motaparthi K, Stanisic V, Van Voorhees AS, et al. From themedical board of the national psoriasis foundation:recommendations for screening for hepatitis B infection prior toinitiating anti-tumor necrosis factor-alfa inhibitors or otherimmunosuppressive agents in patients with psoriasis[j]. J Am AcadDermatol, 2014,70( 1): 178-186.
  • 9Wilsmann-Theis D, Fronhoffs K, Ehler LK,et al. Low-dose metho-trexate -a therapeutical kick in TNF-alpha antagonist treatment forrecalcitrant psoriasis vulgaris[j]. Dermatol Ther, 2014,27( 1): 55-59.
  • 10刘伦飞,郑敏.英夫利西单抗在银屑病中的应用进展[J].中华皮肤科杂志,2013,46(3):216-219. 被引量:6

二级参考文献27

  • 1Kimber I,Cumberbatch M, Dearman RJ, et al. Cytokines andchemokines in the initiation and regulation of epidermal Langer-hans cell mobilization. Br J Dermatol, 2000, 142(3): 401-412.
  • 2Pastore S, Gubinelli E, Leoni L, et al. Biological drugs targetingthe immune response in the therapy of psoriasis. Biologies,2008,2(4): 687-697.
  • 3Griffiths CE, Barker JN. Pathogenesis and clinical features ofpsoriasis. Lancet, 2007, 370(9583): 263-271.
  • 4Pasparakis M, Courtois G, Hafner M, et al. TNF-mediatedinflammatory skin disease in mice with epidermis-specificdeletion of IKK2. Nature, 2002, 417(6891): 861-866.
  • 5Raho G, Vena GA, Bizzoca A, et al. Influence of infliximab onkeratinocyte apoptosis in psoriasis patients. ImmunopharmacolImmunotoxicol, 2011, 33(1): 227-231.
  • 6Reich K, Nestle FO, Papp K, et al. Infliximab induction andmaintenance therapy for moderate-to-severe psoriasis: a phaseIII, multicentre, double-blind trial. Lancet, 2005,366 (9494):1367-1374.
  • 7Menter A, Feldman SR,Weinstein GD, et al. A randomizedcomparison of continuous vs. intermittent infliximab maintenanceregimens over 1 year in the treatment of moderate-to-severeplaque psoriasis. J Am Acad Dermatol, 2007, 56( 1): 31.el-15.
  • 8Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment oftumour necrosis factor antagonists in the treatment of psoriasis.Br J Dermatol, 2010, 162(6): 1349-1358.
  • 9Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatmentsfor moderate to severe plaque psoriasis: systematic review andmeta-analysis. Dermatology, 2009, 219(3): 209-218.
  • 10Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drugsurvival rates for adalimumab, etanercept and infliximab in pa-tients with psoriasis vulgaris. Br J Dermatol, 2011,164(5):1091-1096.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部